Stock-Based Compensation (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2021 |
May 11, 2021 |
Apr. 09, 2021 |
Jan. 06, 2021 |
Aug. 12, 2020 |
Aug. 01, 2020 |
Jul. 15, 2020 |
Jul. 14, 2020 |
Jun. 30, 2021 |
Mar. 31, 2022 |
Mar. 31, 2021 |
|
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of fully vested option exercisable | 2,097,917 | ||||||||||
| Stock options requiring assessment of value | 0 | ||||||||||
| Stock option vested exercisable term | 15 months | ||||||||||
| Stock based compensation | $ 339,672 | $ 656,032 | |||||||||
| Total deferred compensation expense for outstanding value of unvested stock options | 1,757,000 | ||||||||||
| Intrinsic value of exercisable but unexercised in-the-money stock options | $ 11,000 | ||||||||||
| Fair market value, per share | $ 1.23 | ||||||||||
| Outstanding stock options to acquire shares of common stock not vested | 568,750 | ||||||||||
| Dr. Winson Sze Chun Ho [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of fully vested option issued | 50,000 | ||||||||||
| Dr. Yun Yen [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of fully vested option issued | 50,000 | ||||||||||
| Dr. Stephen Forman [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of fully vested option issued | 50,000 | ||||||||||
| Philip Palmedo [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of fully vested option issued | 50,000 | ||||||||||
| Eric J. Forman [Member] | Employment Agreement [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Stock options description | On July 15, 2020, as amended on August 12, 2020, in connection with the employment agreement entered into with Eric J. Forman, Mr. Forman was granted options for 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested as to 25% on August 12, 2020 and August 12, 2021, and will vest 25% on each of the second and third anniversaries of the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the stock options fully-vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months ended March 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,710 and $24,710, respectively, with respect to these stock options | ||||||||||
| Stock options granted to purchase common stock, issued | 58,333 | ||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||
| Stock options are exercisable price per share | $ 7.14 | ||||||||||
| Fair value of stock options | $ 400,855 | ||||||||||
| Stock price per share | $ 6.8718 | ||||||||||
| Stock options fully vested amount, fair value | $ 100,214 | ||||||||||
| Stock based compensation | $ 24,710 | 24,710 | |||||||||
| Dr. James Miser [Member] | Employment Agreement [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Stock options description | Dr. James S. Miser, M.D., Dr. Miser was granted options for 83,334 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the effective date of the employment agreement. The options vested as to 25% on August 1, 2020 and August 1, 2021, and will vest 25% on each of the second and third anniversaries of the effective date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $572,650 ($6.8718 per share), of which $143,163 was attributable to the stock options fully-vested on August 1, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 1, 2020 through August 1, 2023. During the three months ended March 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $35,300 and $35,300, respectively, with respect to these stock options | ||||||||||
| Stock options granted to purchase common stock, issued | 83,334 | ||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||
| Stock options are exercisable price per share | $ 7.14 | ||||||||||
| Fair value of stock options | $ 572,650 | ||||||||||
| Stock price per share | $ 6.8718 | ||||||||||
| Stock options fully vested amount, fair value | $ 143,163 | ||||||||||
| Stock based compensation | 35,300 | 35,300 | |||||||||
| Robert N. Weingarten [Member] | Employment Agreement [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Stock options description | On August 12, 2020, in connection with the employment agreement entered into with Robert N. Weingarten, Mr. Weingarten was granted options for 58,333 shares of the Company’s common stock. The options can be exercised on a cashless basis. The options have a term of five years and an exercise price of $7.14 per share, which was equal to the closing market price of the Company’s common stock on the grant date. The options vested as to 25% on August 12, 2020 and August 12, 2021, and will vest 25% on each of the second and third anniversaries of the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $400,855 ($6.8718 per share), of which $100,214 was attributable to the stock options fully-vested on August 12, 2020 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from August 12, 2020 through August 12, 2023. During the three months ended March 31, 2022 and 2021, the Company recorded charges to general and administrative costs in the consolidated statement of operations of $24,710 and $24,710, respectively, with respect to these stock options | ||||||||||
| Stock options granted to purchase common stock, issued | 58,333 | ||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||
| Stock options are exercisable price per share | $ 7.14 | ||||||||||
| Fair value of stock options | $ 400,855 | ||||||||||
| Stock price per share | $ 6.8718 | ||||||||||
| Stock options fully vested amount, fair value | $ 100,214 | ||||||||||
| Stock based compensation | 24,710 | $ 24,710 | |||||||||
| Non Officer Directors [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Stock vesting description | Stock-based features of the compensation package consisted of the annual granting of stock options to each non-officer director to purchase 100,000 shares of common stock at the closing market price on the earlier of the date of the annual meeting of shareholders or the last business day of the month ending June 30, vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested | ||||||||||
| Number of fully vested option exercisable | 500,000 | 100,000 | 500,000 | ||||||||
| Stock options description | the Board of Directors, in accordance with the recently adopted cash and equity compensation package for the members of the Board of Directors, granted to each of the five non-officer directors of the Company stock options exercisable for a period of five years to purchase 100,000 shares (a total of 500,000 shares) of the Company’s common stock at an exercise price of $3.03 per share (the closing market price on the grant date), vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The total fair value of the 500,000 stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $1,421,095 ($2.84225 per share), which is being charged to operations ratably from July 1, 2021 through June 30, 2023. During the three months ended March 31, 2022, the Company recorded a charge to general and administrative costs in the consolidated statement of operations of $175,205 with respect to these stock options. | ||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||
| Stock options are exercisable price per share | $ 3.03 | $ 3.03 | |||||||||
| Fair value of stock options | $ 1,421,095 | ||||||||||
| Stock price per share | $ 2.84225 | $ 2.84225 | |||||||||
| Stock based compensation | 175,205 | ||||||||||
| Stock options granted to purchase common stock, issued | 500,000 | ||||||||||
| New Director [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Stock vesting description | the granting of stock options to a new director to purchase 250,000 shares of common stock, exercisable at the closing market price on the grant date for a period of five years, vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested | ||||||||||
| Number of fully vested option exercisable | 250,000 | ||||||||||
| Director [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||
| Stock options are exercisable price per share | $ 3.21 | ||||||||||
| Fair value of stock options | $ 571,312 | ||||||||||
| Stock price per share | $ 2.8566 | ||||||||||
| Number of fully vested option issued | 200,000 | ||||||||||
| Director [Member] | Dr. Winson Sze Chun Ho [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of fully vested option exercisable | 250,000 | ||||||||||
| Stock options description | Winson Sze Chun Ho resigned from the Company’s Board of Directors to focus on clinical and pre-clinical cancer research in academic medicine. Concurrent with his resignation, the Board of Directors appointed Gil Schwartzberg to fill the vacancy created by Dr. Ho’s resignation. In connection with his appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Mr. Schwartzberg was granted options exercisable for a period of five years to purchase 250,000 shares of the Company’s common stock at an exercise price of $3.20 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $753,611 ($3.0144 per share), of which $376,800 was attributable to the stock options fully-vested on April 9, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from April 9, 2021 through June 30, 2023. During the three months ended March 31, 2022, the Company recorded a charge to general and administrative costs in the consolidated statement of operations of $41,764 with respect to these stock options. | ||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||
| Stock options are exercisable price per share | $ 3.20 | ||||||||||
| Fair value of stock options | $ 753,611 | ||||||||||
| Stock price per share | $ 3.0144 | ||||||||||
| Stock options fully vested amount, fair value | $ 376,800 | ||||||||||
| Stock based compensation | 41,764 | ||||||||||
| Director [Member] | Ms.Regina Brown [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of fully vested option exercisable | 250,000 | ||||||||||
| Stock options description | the Board of Directors appointed Regina Brown to the Board of Directors. In connection with her appointment to the Board of Directors, and in accordance with the Company’s cash and equity compensation package for members of the Board of Directors, Ms. Brown was granted options exercisable for a period of five years to purchase 250,000 shares of the Company’s common stock at an exercise price of $2.80 per share (the closing market price on the grant date), vesting 50% on the grant date and the remainder vesting 12.5% on the last day of each subsequent calendar quarter-end until fully vested. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $658,363 ($2.6335 per share), of which $329,188 was attributable to the stock options fully-vested on May 11, 2021 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options is being charged to operations ratably from May 11, 2021 through June 30, 2023. During the three months ended March 31, 2022, the Company recorded a charge to general and administrative costs in the consolidated statement of operations of $37,983 with respect to these stock options. | ||||||||||
| Stock option vested exercisable term | 5 years | ||||||||||
| Stock options are exercisable price per share | $ 2.80 | ||||||||||
| Fair value of stock options | $ 658,363 | ||||||||||
| Stock price per share | $ 2.6335 | ||||||||||
| Stock options fully vested amount, fair value | $ 329,188 | ||||||||||
| Stock based compensation | $ 37,983 | ||||||||||
| Five Non Officer Directors [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of fully vested option exercisable | 100,000 | 100,000 | |||||||||
| 2020 Stock Incentive Plan [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Shares issued | 1,400,000 | ||||||||||
| Shares outstanding | 1,400,000 | ||||||||||
| Shares were available for issuance | 933,333 | ||||||||||
| 2020 Stock Incentive Plan [Member] | Maximum [Member] | |||||||||||
| Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | |||||||||||
| Number of restricted stock issued | 2,333,333 | ||||||||||